The Lunit study found that patients with higher pre-treatment iTIL density showed a 51% lower risk of disease progression or death. Credit: Shutterstock / The Green foto

South Korean artificial intelligence (AI) company Lunit has revealed results  from a trial of its system ability to predict immunotherapy treatment outcomes in rare tumours, finding it able to lower the risk of disease progression or death by as much as 51%.

The full results are set to be announced as part of the Texas-based Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting. The company announced that patients whose tumour samples displayed AI-detected changes in both intratumoral immune cell (intratumoral tumour-infiltrating lymphocyte; iTIL) presence and tumour content were significantly more likely to have better treatment outcomes and respond positively to immunotherapy treatment.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Utilising the company’s Lunit SCOPE IO system to assess patient tumours, both those in pre-treatment and on-treatment biopsies from patients with rare tumours receiving pembrolizumab, the study examined more than 500 slides across more than 10 different rare tumour types. Now, the company has concluded that the AI system can effectively identify specific patterns in tumor samples that correlate with better treatment outcomes.

The study found that patients with higher pre-treatment iTIL density showed a 51% lower risk of disease progression or death. Patients who had greater iTIL density increase at on-treatment biopsy showed a 35% lower risk of disease progression. Patients who experienced both a greater iTIL density increase and tumour content decrease saw the highest results, with a 68% lower risk of disease progression or death.

Brandon Suh, CEO of Lunit, said: “These findings highlight how our AI technology can provide deep insights into the unique and challenging tumour microenvironment seen in rare cancers, and represent a critical advancement in our understanding of rare tumour biology.

“This study has demonstrated the value of Lunit SCOPE IO in an important clinical setting, showcasing its potential to personalize treatment for patients who have limited therapeutic options. We believe these advancements are a testament to the transformative impact AI can have on oncology and patient outcomes.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The results follow Lunit’s partnership with Roche to integrate the company’s SCOPE PD-L1 AI diagnosis tool with Roche’s Digital Pathology platform. Elsewhere in the Korean market, researchers at Seoul’s Chung-Ang University have developed a new, non-invasive method form of biosensor designed for the early detection of kidney disease.